FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
FGENSAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025, in New York, NY.
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation
FGENSAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited, pursuant to the Share Purchase Agreement, dated February 20, 2025.
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update
FGENSAN FRANCISCO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2025 and provided an update on the company’s recent developments.
HC Wainwright & Co. Reiterates Buy on FibroGen, Maintains $10 Price Target
FGENFibroGen Q1 EPS $0.05 Beats $0.02 Estimate, Sales $2.74M Beat $2.00M Estimate
FGENA Preview Of FibroGen's Earnings
FGENFibroGen Announces Publication Of Results From Phase 1 Monotherapy Study Of FG-3246 In Patients With Metastatic Castration-Resistant Prostate Cancer In Journal of Clinical Oncology; Says Initiation Of Phase 2 Monotherapy Dose Optimization Study Of FG-3246
FGENHC Wainwright & Co. Reiterates Buy on FibroGen, Maintains $10 Price Target
FGENFibroGen Q4 EPS From Continuing Operations $(0.08), Revenue From Continuing Operations $3.100M
FGENHC Wainwright & Co. Reiterates Buy on FibroGen, Maintains $10 Price Target
FGEN